Oral GLP-1 receptor agonists are generating a great deal of excitement as a potential inflection point in diabetes and ...

The daily pill, called Foundayo, could make it easier for more people to lose weight.

Eli Lilly announced this morning that the FDA has, as was expected, approved its oral GLP-1, orforglipron, as treatment for ...

ATTAIN demonstrated placebo-adjusted weight reductions of roughly 9–11 percentage points at 72 weeks, with 27.3 lb (12.4%) ...

In phase 3 clinical trials, orforglipron was associated with significant reductions in mean percent body weight compared with placebo in patients with and without type 2 diabetes.

Originally developed for Type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the weight-loss medication market. And in recent years, their popularity has soared due to ...

MedImpact Healthcare Systems, Inc. MedImpact redefines obesity care with new suite of GLP-1 solutions. Published March 24, ...

Orforglipron (LY3502970) is a small-molecule, non-peptide GLP-1RA designed for oral use. Compared to popular GLP-1RAs like semaglutide, orforglipron does not require injection or an absorption ...

Oral semaglutide (Wegovy; Novo Nordisk) expands GLP-1 weight-loss options, but pharmacy budgets and health care cost pressures persist. The glucagon-like peptide-1 (GLP-1) class has transformed ...

The first and only oral GLP-1 for weight loss in adults is now available to consumers. Drugmaker Novo Nordisk announced Monday that its daily oral Wegovy pill is now available by prescription.

GLP-1 is a peptide hormone generated from proglucagon that is secreted after meals by enteroendocrine L-cells in the distal jejunum, ileum, and colon. GLP-1 is also produced by pancreatic α-cells and ...

Ozempic 2.0: The arrival of Ozempic and similar GLP-1 drugs has already reshaped medicine and consumer behaviour in ways few anticipated. Millions of people have achieved weight loss at levels ...